Key facts
- This page summarizes Jeanette Weidner's Form 4 filing for Gain Therapeutics, Inc. (GANX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Oct 2026, 17:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The shares underlying the Option shall vest as to 25% on October 29, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
SEC remarks
Principal Accounting Officer and Principal Financial Officer